Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
Lung Cancer
DRUG: Topotecan|DRUG: Docetaxel
Overall response rate
Time to Progression|Overall survival|Overall toxicity
Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms:

* Topotecan
* Docetaxel

For ever 2 patients treated, 1 will receive treatment A (Topotecan) and 1 will receive treatment B (Docetaxel). The study is not blinded so both the patient and the doctor will know which treatment has been assigned.